In this review, we do not focus on describing previously mentioned studies in detail, but we thoroughly describe the effects of both maximal androgen deprivation and PARP inhibition on the prostate cancer cell and hypothesize how a potential synergistic effect of combining both treatments can be explained at the molecular level in non-HRR-mutated patients. Here, PARP1 is linked to prostate carcinoma.